Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Bovine, Human|
|Host / Isotype||Sheep / IgG|
|Immunogen||Synthetic peptide corresponding to residues (L(946) K R K R K I L S S D D S L R S S(962) of human LRRK2 protein.|
|Storage buffer||whole serum|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunohistochemistry (Frozen) (IHC (F))||1:500|
|Immunohistochemistry (Paraffin) (IHC (P))||1:500|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA1-18254 detects LRRK2 from human samples.
PA1-18254 has been successfully used in immunohistochemistry (paraffin and frozen) procedures.
The PA1-18254 immunogen is a synthetic peptide corresponding to residues (L(946) K R K R K I L S S D D S L R S S(962) of human LRRK2 protein, conjugated to Blue Carrier Protein.
Reconstitute with 100 ul of distilled water.
Defects in LRRK2 are the cause of Parkinson disease 8 (PARK8). Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK8 is an autosomal-dominant late-onset parkinsonism, characterized by onset from 50 to 65 years, with slow progression and relatively benign course.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
augmented in rheumatoid arthritis 17; Dardarin; leucine-rich repeat kinase 2; Leucine-rich repeat serine/threonine-protein kinase 2; PARK8
AURA17; BOS_5208; DARDARIN; LRRK2; PARK8; RIPK7; ROCO2